vtx logo

request clinical advice

vtx logo sticky

scott@vtx-cpd.com

Forum Replies Created

Viewing 15 posts - 31 through 45 (of 2,254 total)
  • Author
    Posts
  • scott@vtx-cpd.com
    Keymaster

    Replying to Liz Bode 11/06/2025 - 20:20

    Really interesting!

    I presume there are dog studies ongoing? I will also presume the study will have a cool name… like all the other cardiology studies!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Liz Bode 11/06/2025 - 20:27

    Thanks Liz.

    I think the ‘furosemide or nit’ question is always on people minds in these cases.

    Any other treatment tips or tricks? I think time and supportive care seems like the key here!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Thanks Janette – this is a really valuable summary and I appreciate the link to the review. The balance between neonatal vitality and maternal welfare is often overlooked in practice.

    What’s your current go-to for premeds in emergency C-sections?

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Janette B. 01/06/2025 - 18:12

    Brilliant!

    Thank you!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Mark Laloo 10/06/2025 - 12:55

    Great questions!

    I will make sure Sam sees them!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Samantha T. 05/06/2025 - 14:40

    Hey Sam!

    Thank you so much for your input and for your brilliant sessions!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Josep B. 02/06/2025 - 04:52

    Thanks Josep!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Steph Sorrell 02/06/2025 - 09:24

    Thanks Steph!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Thanks Mark.

    Your go-to combination of buprenorphine, gabapentin, and meloxicam is very similar to what many of us reach for in the first instance, and there’s sound rationale behind each. That said, it’s worth keeping in mind that while these medications are commonly used and make intuitive sense in painful inflammatory bladder conditions, none of them have been robustly studied for non-obstructive FIC in terms of efficacy beyond placebo.

    In fact, a recent consensus summary (authored by the amazing Sam Taylor) highlights that analgesics such as NSAIDs, opioids, gabapentinoids, and even frunevetmab (anti-NGF monoclonal antibody) have not yet been formally evaluated in clinical trials for this indication. That doesn’t mean they shouldn’t be used—pain management is absolutely recommended—but it does mean we need to weigh their potential benefits against the stress of administration, especially when oral dosing is difficult or negatively affects cat behaviour. Gabapentin is helpful in many cats, but we have to be honest that in some cases, the stress of medicating may actually worsen the condition by increasing perceived threat and reducing control.

    Other drugs like prednisolone, pentosan polysulfate, and glycosaminoglycans have not shown significant benefit in blinded studies, although both placebo and treatment groups often improve—possibly related to better home care, handling, or reduced threat perception (e.g. giving meds in a treat or encouraging owner-cat bonding). These behavioural and environmental influences may explain why MEMO (multimodal environmental modification) consistently shows better long-term results than medications alone.

    Trazodone is one I’ve seen used selectively in cats that are extremely hypervigilant or live in high-arousal home environments, but I rarely use it personally.

    Amitriptyline and fluoxetine remain options in refractory or relapsing cases, particularly if there’s concurrent urine spraying or clear evidence of chronic stress or anxiety. However, these should ideally be started with behavioural guidance and close follow-up. Fluoxetine has been associated with urinary retention in some reports, and any use for behavioural modification should always accompany MEMO, not replace it.

    I am not a huge fan of subcutaneous fluids in these cases. There’s no evidence it improves outcome, but it may make sense on a case-by-case basis. I wouldn’t do it routinely unless there’s a clear clinical rationale.

    I’ll also make sure Sam sees this!

    Consensus guideline link: https://journals.sagepub.com/doi/10.1177/1098612X241309176

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Mark Laloo 28/05/2025 - 18:12

    Thanks Mark!

    I agree. I rarely use ketamine for sedation now.

    Alfaxalone is a very useful drug!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hi Mark,

    Thanks so much for the questions.

    For FMT in cats, the core principles mirror canine protocols, though feline-specific studies are limited. Donors should ideally be healthy indoor-only cats with no history of GI disease, recent antimicrobials, or ongoing medication. Screening typically includes CBC/biochem, faecal float, Giardia ELISA, and a full PCR panel for infectious enteropathogens. Some centres pool donor faeces, but single-donor protocols tend to be preferred for traceability and consistency.

    Material is usually fresh (processed and administered within 6 hours), though frozen samples (stored at –80°C with 10% glycerol) can be used in some settings. Most transplants are delivered via retention enema under light sedation, though oral and nasoesophageal approaches are being explored. A typical course involves 1–3 treatments depending on response. To be honest I will actually GA my feline transplant patients due to the higher risk of aspirating the transplanted material than dogs.

    It’s also worth flagging a recent feline case series in JFMS (Lee et al., 2025; DOI: 10.1177/1098612X251337274), which describes adverse events in nine cats undergoing FMT. These included lethargy, vomiting, diarrhea, inappetence, weight loss, and transient GI pain. Events were managed with antimicrobials, antiemetics, and supportive care. Importantly, 8/9 cats still showed positive clinical response (7 complete, 1 partial), highlighting both the potential and the need for caution.

    For a great recent review of both FMT and probiotics in small animals, including practical donor selection and preparation advice, you might also find this helpful:

    https://www.advancesinsmallanimalcare.com/article/S2666-450X(24)00006-3/fulltext

    On the probiotic front, Vivomixx, Visbiome, and Sivomixx probably represent the most evidence-based blends in terms of documented strain content, viability, and peer-reviewed outcomes—particularly in dogs, though feline data is building. Visbiome Vet has the most strain-specific research and independent verification of capsule content. Fortiflora is still widely used and palatable, but contains only one strain and less independent efficacy data.

    I’ll also make sure Steph sees your comment, I’d be really interested in her thoughts.

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Mark Laloo 28/05/2025 - 17:44

    Hi Mark,

    Thanks so much for your thoughtful response. I completely agree that having a standardised approach helps immensely with both consistency and team confidence.

    The use of subcutaneous insulin alongside IV insulin in DKA isn’t well supported by current evidence, and most guidelines still recommend against it during the acute phase. The concern is that SC absorption is unreliable in dehydrated or vasoconstricted patients, and combining routes can complicate interpretation of response and titration. That said, I’ve also heard of it being used in transition phases, or when IV access becomes a limitation—but like you, I prefer to wait until hydration has been restored and enteral intake has resumed before switching over.

    On the topic of alternative approaches, there are two small studies worth noting: the 2013 JVECC study by Marshall et al. (DOI: 10.1111/vec.12038) looked at IM glargine (with or without SC glargine) in 15 cats with DKA. All survived to discharge with a median hospital stay of 4 days. A later randomized trial by Gallagher et al. in 2014 (JVECC, DOI: 10.1111/vec.12269) compared IM/SC insulin to a CRI of regular insulin. The SC/IM group had significantly faster resolution of ketonemia and acidosis, and shorter hospitalization. Small numbers, but potentially practice-informing in the right setting.

    I completely agree that electrolyte management is often the most challenging and dynamic part of these cases. I’d love to hear more about how your team handles potassium and phosphate adjustments—do you work from a fixed supplementation chart or tailor it dynamically?

    Euglycaemic DKA has become such a hot topic in human endocrinology with SGLT2 inhibitors. How were you monitoring for it in those cats, and what approach did you take once it was identified?

    I’ll also make sure Rodolfo sees this—it’ll be really interesting to hear his take too.

    Thanks again for a great discussion.

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hi Kath,

    Thanks for posting. Such a great case to spark discussion. In these scenarios, I always find the biggest challenge is how we prioritise interventions and manage the balance between risk and benefit. How aggressive should we be with fluid resuscitation? When and how do we give analgesia safely? And how much do we try to correct before heading to surgery?

    Curious to hear how you prioritise.

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Hi Christina,

    Thanks so much for sharing—what a tough case. I think Josep’s nailed this one and has covered all the key angles better than I could, so I’ll defer to him here!

    Scott 🙂

    scott@vtx-cpd.com
    Keymaster

    Replying to Rachel H. 29/05/2025 - 15:18

    No problem!

    Let me know if there is anything else I can do to help.

    Have an amazing weekend.

    Scott 🙂

Viewing 15 posts - 31 through 45 (of 2,254 total)